{"doi":"10.3390/nano10101988","title":"Ni-Cu Nanoparticles and Their Feasibility for Magnetic Hyperthermia","abstract":"Ni-Cu nanoparticles have been synthesized by reducing Ni and Cu from metal precursors using a sol–gel route followed by annealing at 300 °C for 1, 2, 3, 6, 8, and 10 h for controlled self-regulating magnetic hyperthermia applications. Particle morphology and crystal structure revealed spherical nanoparticles with a cubic structure and an average size of 50, 60, 53, 87, and 87 nm for as-made and annealed samples at 300 °C for 1, 3, 6, and 10 h, respectively. Moreover, hysteresis loops indicated ferromagnetic behavior with saturation magnetization (Ms) ranging from 13–20 emu/g at 300 K. Additionally, Zero-filed cooled and field cooled (ZFC-FC) curves revealed that each sample contains superparamagnetic nanoparticles with a blocking temperature (TB) of 196–260 K. Their potential use for magnetic hyperthermia was tested under the therapeutic limits of an alternating magnetic field. The samples exhibited a heating rate ranging from 0.1 to 1.7 °C/min and a significant dissipated heating power measured as a specific absorption rate (SAR) of 6–80 W/g. The heating curves saturated after reaching the Curie temperature (Tc), ranging from 30–61 °C within the therapeutic temperature limit. An in vitro cytotoxicity test of these Ni-Cu samples in biological tissues was performed via exposing human breast cancer MDA-MB231 cells to a gradient of concentrations of the sample with 53 nm particles (annealed at 300 °C for 3 h) and reviewing their cytotoxic effects. For low concentrations, this sample showed no toxic effects to the cells, revealing its biocompatibility to be used in the future for in vitro/in vivo magnetic hyperthermia treatment of cancer.","journal":"Nanomaterials","year":2020,"id":75411,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":25,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9466,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":393500,"name":"Edgar A. Borrego","orcid":"0009-0009-5432-8267","position":1,"is_corresponding":false},{"id":394325,"name":"Dawn S. Blazer","orcid":null,"position":2,"is_corresponding":false},{"id":393501,"name":"Mohamed Fathi Sanad","orcid":"0000-0002-8174-4356","position":3,"is_corresponding":false},{"id":393502,"name":"Shirin Pourmiri","orcid":"0000-0002-8835-5978","position":4,"is_corresponding":false},{"id":393503,"name":"Denisse A. Gutiérrez","orcid":"0000-0001-5421-2242","position":5,"is_corresponding":false},{"id":393504,"name":"Armando Varela-Ramı́rez","orcid":"0000-0002-2071-4874","position":6,"is_corresponding":false},{"id":393505,"name":"G. C. Hadjipanayis","orcid":"0000-0002-8813-2635","position":7,"is_corresponding":false},{"id":394326,"name":"Ahmed A. El‐Gendy","orcid":null,"position":8,"is_corresponding":false},{"id":393499,"name":"Bianca P. Meneses-Brassea","orcid":"0000-0002-1411-9569","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-18T21:46:33.313355Z","pmid":"33050215","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}